Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis.

Han X, Medeiros LJ, Abruzzo LV, Jones D, Lin P.

Am J Clin Pathol. 2006 Jan;125(1):49-56.

PMID:
16482991
2.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.

N Engl J Med. 2002 Aug 15;347(7):481-7.

3.

Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia.

Nadal N, Flandrin P, Cornillon J, Delabesse E, Mauvieux L, Olaru D, Morel S, Campos L.

Cancer Genet Cytogenet. 2006 Sep;169(2):174-5. No abstract available.

PMID:
16938578
4.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.

5.

Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.

Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC.

Blood. 2003 Dec 1;102(12):4187-90. Epub 2003 Aug 7.

6.

A case of biphenotypic blast crisis of unclassified myeloproliferative disorder.

Kim J, Park CJ, Seo EJ, Lee JH, Yoo SJ, Choi SJ, Chi HS.

Ann Hematol. 2002 Oct;81(10):603-4. Epub 2002 Oct 17.

PMID:
12424544
7.

Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.

Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R.

Am J Clin Pathol. 2006 Oct;126(4):530-3.

PMID:
16938665
8.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
9.

Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia.

Baranger L, Szapiro N, Gardais J, Hillion J, Derre J, Francois S, Blanchet O, Boasson M, Berger R.

Br J Haematol. 1994 Oct;88(2):343-7. Review.

PMID:
7803280
10.

Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.

Wang Y, Wu D, Sun A, Jin Z, Qiu H, Miao M, Tang X, Fu Z.

Int J Hematol. 2008 Mar;87(2):167-71. doi: 10.1007/s12185-008-0032-4. Epub 2008 Feb 22.

PMID:
18288566
12.

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.

Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F.

Cancer. 2006 Sep 1;107(5):1008-13.

13.

Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate.

Iyama S, Matsunaga T, Sato T, Murase K, Araki N, Takimoto R, Kobune M, Sagawa T, Takayama T, Niitsu Y.

Intern Med. 2008;47(8):791-4. Epub 2008 Apr 16.

14.

[Two cases of unclassified chronic myeloproliferative disorders].

Hirano A, Takahashi I, Haruta Y, Nakamura T, Nakata H, Yorimitsu S, Sekito N, Kimura I.

Rinsho Ketsueki. 1992 Apr;33(4):525-31. Japanese.

PMID:
1602619
15.

A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.

Bacher U, Haferlach T, Kern W, Harich HD, Schnittger S, Haferlach C.

Cancer Genet Cytogenet. 2007 May;175(1):52-6.

PMID:
17498558
16.

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.

Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, Prümmer O, Rauh S, Hehlmann R, Hochhaus A, Cross NC, Reiter A.

Haematologica. 2007 Feb;92(2):163-9.

17.

Acquired gain of an X chromosome as the sole abnormality in the blast crisis of chronic neutrophilic leukemia.

Yamamoto K, Nagata K, Kida A, Hamaguchi H.

Cancer Genet Cytogenet. 2002 Apr 1;134(1):84-7. Review.

PMID:
11996803
18.

Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).

Shin J, Kim M, Kim DB, Yeom JO, Lee HJ, Cho SG.

Acta Haematol. 2008;119(1):57-9. doi: 10.1159/000115966. Epub 2008 Feb 12. No abstract available.

PMID:
18268406
19.

A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case.

Yan J, Whittom R, Delage R, Drouin R.

Cancer Genet Cytogenet. 2003 Jan 15;140(2):138-44.

PMID:
12645652
20.

Enzyme negative blastic transformation of chronic myeloproliferative disorders: immunophenotyping of the blastic cell population.

Matolcsy A, Izer I, Magyarlaki T, Baranyay F.

Haematologia (Budap). 1991;24(1):27-37.

PMID:
1813360

Supplemental Content

Support Center